Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li C Cheung

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or lessHormuzd A Katki, Julia C Gage, Mark Schiffman, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment managementHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelinesHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positiveHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 yearsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
JAMA Network Open|September 18, 2023
Methods for Using Race and Ethnicity in Prediction Models for Lung Cancer Screening EligibilityRebecca Landy, Isabel Gomez, Tanner J Caverly, et al.
Journal of Lower Genital Tract Disease|September 28, 2017
Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening GuidelinesMaria Demarco, Thomas S Lorey, Barbara Fetterman, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or lessHormuzd A Katki, Julia C Gage, Mark Schiffman, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment managementHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelinesHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positiveHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 yearsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.
JAMA Network Open|September 18, 2023
Methods for Using Race and Ethnicity in Prediction Models for Lung Cancer Screening EligibilityRebecca Landy, Isabel Gomez, Tanner J Caverly, et al.
Journal of Lower Genital Tract Disease|September 28, 2017
Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening GuidelinesMaria Demarco, Thomas S Lorey, Barbara Fetterman, et al.
Pageof 10